Onconova reports PhIII flop, putting high-risk MDS program on the chopping block
Beleaguered biotech Onconova ran into another setback Monday morning as a Phase III for its lead program flopped once again.
The trial results for rigosertib …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
